SG11202004965RA - Methods of treatment with asparaginase - Google Patents
Methods of treatment with asparaginaseInfo
- Publication number
- SG11202004965RA SG11202004965RA SG11202004965RA SG11202004965RA SG11202004965RA SG 11202004965R A SG11202004965R A SG 11202004965RA SG 11202004965R A SG11202004965R A SG 11202004965RA SG 11202004965R A SG11202004965R A SG 11202004965RA SG 11202004965R A SG11202004965R A SG 11202004965RA
- Authority
- SG
- Singapore
- Prior art keywords
- asparaginase
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/82—Asparaginase (3.5.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762592982P | 2017-11-30 | 2017-11-30 | |
US201862625078P | 2018-02-01 | 2018-02-01 | |
US201862631142P | 2018-02-15 | 2018-02-15 | |
US201862673075P | 2018-05-17 | 2018-05-17 | |
PCT/US2018/063448 WO2019109018A1 (en) | 2017-11-30 | 2018-11-30 | Methods of treatment with asparaginase |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202004965RA true SG11202004965RA (en) | 2020-06-29 |
Family
ID=66664263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202004965RA SG11202004965RA (en) | 2017-11-30 | 2018-11-30 | Methods of treatment with asparaginase |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230173042A1 (en) |
EP (1) | EP3716997A4 (en) |
JP (2) | JP2021505661A (en) |
KR (1) | KR20200119234A (en) |
CN (1) | CN111818937A (en) |
AU (1) | AU2018375183A1 (en) |
BR (1) | BR112020010976A2 (en) |
CA (2) | CA3083499A1 (en) |
IL (1) | IL274865A (en) |
MX (1) | MX2020005567A (en) |
SG (1) | SG11202004965RA (en) |
WO (1) | WO2019109018A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY37341A (en) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
GB201912020D0 (en) * | 2019-08-21 | 2019-10-02 | Porton Biopharma Ltd | Therapeutic Conjugate |
CA3156066A1 (en) * | 2019-10-25 | 2021-04-29 | Mi Rim Choi | Recombinant l-asparaginase |
WO2022211829A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
WO2024015529A2 (en) | 2022-07-14 | 2024-01-18 | Jazz Pharmaceuticals Ireland Ltd. | Combination therapies involving l-asparaginase |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004515232A (en) * | 2000-11-28 | 2004-05-27 | フエニツクス・フアーマコロジクス・インコーポレーテツド | Modified arginine deiminase |
CN1360049A (en) * | 2000-12-20 | 2002-07-24 | 上海博德基因开发有限公司 | Polypeptide-human L-asparaginase 24.53 and polynucleotide for coding it |
WO2007103290A2 (en) * | 2006-03-03 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
ITMI20060612A1 (en) * | 2006-03-30 | 2007-09-30 | Keryos Spa | NEW ACTIVADED POLY-ETHYLENE GLYCOLS-AND RELATED POLYMERS AND THEIR APPLICATIONS |
WO2011003633A1 (en) * | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
EP2827878A1 (en) * | 2012-03-21 | 2015-01-28 | Erytech Pharma | Medicament for the treatment of acute myeloid leukemia (aml) |
CN105802948B (en) * | 2014-12-29 | 2020-06-09 | 江苏众红生物工程创药研究院有限公司 | Polyethylene glycol site-directed modified asparaginase and preparation method and application thereof |
CN105802946A (en) * | 2014-12-29 | 2016-07-27 | 江苏众红生物工程创药研究院有限公司 | PEGylated asparaginase and applications thereof |
WO2018085493A1 (en) * | 2016-11-04 | 2018-05-11 | Georgia State University Research Foundation, Inc. | Endotoxin free asparaginase |
-
2018
- 2018-11-30 JP JP2020548883A patent/JP2021505661A/en active Pending
- 2018-11-30 EP EP18884437.7A patent/EP3716997A4/en active Pending
- 2018-11-30 KR KR1020207018920A patent/KR20200119234A/en not_active Application Discontinuation
- 2018-11-30 SG SG11202004965RA patent/SG11202004965RA/en unknown
- 2018-11-30 AU AU2018375183A patent/AU2018375183A1/en active Pending
- 2018-11-30 MX MX2020005567A patent/MX2020005567A/en unknown
- 2018-11-30 BR BR112020010976-2A patent/BR112020010976A2/en unknown
- 2018-11-30 CA CA3083499A patent/CA3083499A1/en active Pending
- 2018-11-30 US US16/767,920 patent/US20230173042A1/en active Pending
- 2018-11-30 WO PCT/US2018/063448 patent/WO2019109018A1/en unknown
- 2018-11-30 CA CA3240356A patent/CA3240356A1/en active Pending
- 2018-11-30 CN CN201880084869.5A patent/CN111818937A/en active Pending
-
2020
- 2020-05-24 IL IL274865A patent/IL274865A/en unknown
-
2024
- 2024-02-20 JP JP2024023383A patent/JP2024069234A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
Also Published As
Publication number | Publication date |
---|---|
WO2019109018A1 (en) | 2019-06-06 |
AU2018375183A1 (en) | 2020-06-25 |
IL274865A (en) | 2020-07-30 |
BR112020010976A2 (en) | 2020-11-17 |
EP3716997A1 (en) | 2020-10-07 |
JP2024069234A (en) | 2024-05-21 |
EP3716997A4 (en) | 2022-02-23 |
JP2021505661A (en) | 2021-02-18 |
CN111818937A (en) | 2020-10-23 |
CA3240356A1 (en) | 2019-06-06 |
CA3083499A1 (en) | 2019-06-06 |
US20230173042A1 (en) | 2023-06-08 |
KR20200119234A (en) | 2020-10-19 |
MX2020005567A (en) | 2020-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202006746B (en) | Methods of treatment | |
IL274865A (en) | Methods of treatment with asparaginase | |
HK1248552A1 (en) | Method of treatment with tradipitant | |
IL282482A (en) | Protoxin-ii variants and methods of use | |
IL282508A (en) | Protoxin-ii variants and methods of use | |
EP3684342C0 (en) | Method of treatment | |
HK1249865B (en) | Treatment of pain | |
GB201706406D0 (en) | Method of treatment | |
EP3134108A4 (en) | Agents and methods of treatment | |
HK1249866A1 (en) | Methods of treatment with taselisib | |
GB201815588D0 (en) | Method of treatment | |
GB201416832D0 (en) | Methods of treatment | |
GB201511799D0 (en) | Composition and methods of treatment | |
GB201602802D0 (en) | Method of treatment | |
HK1243937A1 (en) | Methods of treating diseases | |
GB201605127D0 (en) | Composition and methods of treatment | |
SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
GB201417248D0 (en) | Compostion and methods of treatment | |
GB201512139D0 (en) | Methods of treatment | |
GB201801249D0 (en) | Methods of treatment | |
GB201720439D0 (en) | Method of treatment | |
GB201718589D0 (en) | Method of treatment | |
GB201709554D0 (en) | Method of treatment | |
GB201706642D0 (en) | Method of treatment | |
GB201706452D0 (en) | Method of treatment |